New Erexafil consumer guide details the current Supplement Facts panel, serving instructions, proprietary-blend disclosure and federal guidance on evaluating dietary supplements.
OGDEN, Utah, October 27, 2026 — Erexafil has published a 2026 consumer ingredient and label guide based on the Supplement Facts and usage information appearing on its current 30-capsule product packaging. The guide identifies five botanical ingredients with individually disclosed amounts and explains how consumers can use the bottle label as the primary reference when reviewing Erexafil ingredients, serving instructions and safety information.
The publication aims to clarify ingredient information for consumers, addressing discrepancies found in online reviews and descriptions. Unlike formulas that place multiple ingredients under a single proprietary-blend total, the current Erexafil label separately identifies the amount of turmeric root powder, beet root powder, nettle root extract, ashwagandha root extract and Tongkat Ali root extract contained in each one-capsule serving.
Erexafil is sold as a dietary supplement and is not an FDA-approved drug. Publication of the new consumer guide does not represent FDA approval of Erexafil, nor does the Supplement Facts panel establish that the finished product has been clinically demonstrated to diagnose, treat, cure or prevent a medical condition. Federal health guidance distinguishes dietary supplements from approved drugs and notes that supplements are not approved by FDA before reaching the public in the same way as medicines.
“The label should be the first place consumers look when they want to know what is actually contained in a dietary supplement,” said Kevin Moore, Media Relations Manager at Erexafil. “The purpose of this guide is to put the serving information, individual ingredient amounts and safety instructions in one place while making a clear distinction between what appears on the label and what research on individual ingredients can establish.”
2026 Erexafil Guide Makes the Current Bottle Label the Primary Reference
The significance of the 2026 guide is its focus on information that consumers can verify directly from the current Erexafil packaging. Instead of beginning with broad statements about expected results, the guide starts with serving size, ingredient amounts, directions for use, storage instructions and cautionary information.
This approach is particularly relevant when consumers encounter different product descriptions through search engines, reviews or third-party websites. Ingredient formulas can change, older information can remain accessible online and articles discussing an individual botanical may not describe the finished commercial product. The guide therefore directs consumers back to the actual bottle when confirming the current formula.
The current Erexafil packaging identifies a serving size of one capsule and lists 30 servings per container. The bottle contains 30 capsules, making the labeled serving and the number of capsules consistent with a 30-serving container.
Erexafil Supplement Facts List Five Botanical Ingredients With Individual Amounts
According to the Supplement Facts panel on the current Erexafil bottle, each one-capsule serving contains five individually quantified botanical ingredients.
The label lists:
-
Turmeric (Curcuma longa) root powder — 150 mg
-
Beet (Beta vulgaris) root powder — 150 mg
-
Nettle (Urtica dioica) root extract, 4:1 — 50 mg
-
Ashwagandha (Withania somnifera) root extract, 20:1 — 50 mg
-
Tongkat Ali (Eurycoma longifolia Jack) root extract, 10:1 — 50 mg
The Supplement Facts panel states that Daily Values have not been established for these ingredients. That notation should not be interpreted as meaning the ingredients have no biological activity; it means that federal Daily Value reference amounts have not been established for those listed botanical ingredients.
Unlike the earlier information sometimes associated with Erexafil online, the current bottle shown for this guide does not list vitamin D3, niacin, zinc or a 545 mg proprietary blend. Consumers reviewing Erexafil information should therefore compare any article or product description with the Supplement Facts panel on the bottle they actually receive.
Erexafil Ingredients Are Disclosed Individually Rather Than as One Proprietary Blend
One notable characteristic of the current Erexafil Supplement Facts panel is that the five principal botanical ingredients are assigned separate quantities. This provides more information than a label that groups several ingredients under one total proprietary-blend weight without specifying individual amounts.
A consumer can see, for example, that turmeric root powder and beet root powder are each listed at 150 mg per capsule, while nettle root extract, ashwagandha root extract and Tongkat Ali root extract are each listed at 50 mg.
The label also provides extract ratios for three ingredients. Nettle is described as a 4:1 root extract, ashwagandha as a 20:1 root extract and Tongkat Ali as a 10:1 root extract. Extract ratios describe aspects of how botanical material has been concentrated, but they should not automatically be interpreted as a direct measure of clinical effectiveness.
The guide therefore reports these values as formulation information rather than using them to predict a particular outcome.
Research on Turmeric Does Not Establish Results for Erexafil
Turmeric, botanically identified as Curcuma longa, is the first ingredient listed on the current Erexafil Supplement Facts panel at 150 mg of root powder per capsule.
The National Center for Complementary and Integrative Health notes that turmeric has been widely studied and that curcumin is one of its major components. However, NCCIH concludes that the available evidence is not sufficient to definitively determine whether turmeric or curcumin provides benefits for many of the health purposes for which supplements are promoted.
That distinction is important when evaluating the Erexafil formula. The product label specifies turmeric root powder rather than a standardized curcumin amount, and research examining particular curcumin preparations cannot automatically be applied to 150 mg of turmeric root powder contained within a multi-ingredient capsule.
NCCIH also reports that orally consumed turmeric can cause digestive effects in some people and advises consumers taking medicines to discuss herbal-product use with their healthcare providers because interactions are possible.
Beet Root Powder Is Listed at 150 Milligrams Per Capsule
Beet root powder is also listed at 150 mg per one-capsule serving, making it equal by labeled weight to the turmeric root powder in the current formula.
Beetroot has been investigated in clinical research largely because some beet preparations contain dietary nitrate. Several studies have examined nitrate-rich beetroot juice or standardized nitrate preparations in relation to cardiovascular measures, but these studies typically specify the amount of nitrate delivered rather than merely the weight of beet root powder.
A 2024 systematic review and meta-analysis involving adults with hypertension evaluated randomized studies of nitrate-rich beetroot juice. The authors reported a reduction in clinical systolic blood pressure but rated the certainty of evidence as low and noted that results should be interpreted cautiously.
Those findings should not be presented as evidence for Erexafil. The current Erexafil label lists 150 mg of beet root powder but does not state the nitrate content of that powder. It therefore is not possible to equate the Erexafil serving with the nitrate quantities evaluated in beetroot-juice clinical trials.
Nettle Root Extract Appears at 50 Milligrams Per Serving
The current formula lists 50 mg of a 4:1 nettle root extract, identified botanically as Urtica dioica.
Nettle has a long history of traditional use, and European regulators maintain a herbal monograph specifically concerning nettle root. The European Medicines Agency identifies Urtica dioica and Urtica urens root within its herbal-medicinal-product framework and has published an updated European Union herbal monograph and assessment report.
Those regulatory assessments concern nettle root generally and do not test or endorse Erexafil. They also do not establish what a 50 mg 4:1 nettle extract will do when combined with the four other botanicals contained in the Erexafil capsule.
For that reason, the consumer guide treats the EMA material as background research about the botanical rather than as product-specific evidence.
Ashwagandha Research Shows Why Extract Details Matter
Erexafil lists 50 mg of ashwagandha root extract at a 20:1 ratio per capsule. Ashwagandha is botanically known as Withania somnifera and has been used historically in traditional Ayurvedic practice.
NCCIH reports that clinical trials have studied various ashwagandha preparations, but many studies have been small and have used differing formulations. NCCIH says some preparations may have evidence relating to areas such as stress or sleep, while evidence remains insufficient or unclear for many other proposed uses.
That variability makes direct dose comparisons difficult. Research involving one standardized ashwagandha preparation should not automatically be used to predict the effects of another extract with a different concentration, preparation method or accompanying ingredients.
NCCIH also identifies safety considerations. It notes that ashwagandha can cause digestive symptoms or drowsiness in some individuals, that rare cases of liver injury have been reported, and that it can interact with certain medications. People with some health conditions, people preparing for surgery and those taking particular medicines may need additional professional guidance.
Tongkat Ali Root Extract Is Listed at a 10:1 Ratio
The fifth botanical listed on the current Supplement Facts panel is Tongkat Ali, or Eurycoma longifolia Jack, root extract. The label identifies 50 mg per capsule at a 10:1 extraction ratio.
Published scientific literature has examined Eurycoma longifolia extracts, but preparations and doses differ significantly between studies. Some clinical studies use specifically standardized commercial extracts rather than a generic root extract, making it inappropriate to assume that results from those preparations apply directly to another formulation.
The Erexafil label does not identify the extract as the same standardized preparation used in any specific clinical trial reviewed for this guide. Accordingly, no product-performance claim is made on the basis of Tongkat Ali research.
This approach is consistent throughout the guide: ingredient research provides scientific context, but it is not presented as proof that Erexafil itself produces the same findings.
Erexafil Reviews Should Separate Ingredient Research From Finished-Product Evidence
People searching for Erexafil reviews may encounter articles that discuss scientific research associated with each botanical. While those sources can help explain what researchers have studied, they do not substitute for a clinical study of the complete Erexafil formulation.
The difference involves more than ingredient names. Research can depend on exact dose, extraction process, chemical standardization, duration of use, study population and the presence or absence of other ingredients.
For example, beetroot trials frequently specify nitrate content. Ashwagandha studies may use extracts standardized to defined constituents, while turmeric studies may examine curcumin or enhanced-bioavailability formulations rather than ordinary turmeric root powder.
A finished capsule containing five different botanical ingredients therefore should not be described as clinically validated merely because research exists on one or more of those plants.
Erexafil Suggested Use States One Capsule Daily
The product label states that adults should take one capsule daily with an 8-ounce glass of water. The directions additionally state that, for best results according to the label, the capsule is taken approximately 20 to 30 minutes before a meal with 8 ounces of water, or as directed by a healthcare professional.
Those directions represent manufacturer usage information rather than clinical guidance. Consumers should follow the instructions appearing on their specific bottle and should not increase the serving based on online recommendations, testimonials or assumptions about botanical ingredients.
The label specifically cautions users not to exceed the recommended dose. That instruction is relevant because taking additional capsules would simultaneously increase exposure to all five botanical ingredients rather than increasing only one component.
Erexafil Safety Information Includes Several Cautions
The current Erexafil packaging provides a caution section instructing pregnant or nursing individuals, people under 18 and people with a known medical condition to consult a physician before using the dietary supplement.
The label also instructs consumers to keep the product out of reach of children and not to use it if the safety seal is damaged or missing. Storage directions state that the bottle should be kept in a cool, dry place away from heat and light.
These statements are particularly important because botanical ingredients can have pharmacological activity and may interact with medicines or other supplements. Consumers who take prescription drugs or multiple dietary supplements should provide the complete ingredient panel to a physician or pharmacist if they have questions about compatibility.
The guide does not characterize Erexafil as universally safe for every person. Individual circumstances, medications, allergies and underlying health conditions can affect whether a dietary supplement is appropriate.
Other Ingredients Listed on the Erexafil Bottle
In addition to the five ingredients appearing in the Supplement Facts panel, the bottle lists several other ingredients used in the manufacture of the capsule.
According to the label, these are gelatin (bovine) capsule, microcrystalline cellulose, magnesium stearate and silicon dioxide.
The presence of a bovine gelatin capsule may be relevant for consumers who avoid animal-derived ingredients for dietary, personal or other reasons. Consumers with specific ingredient requirements should review both the Supplement Facts panel and the “Other Ingredients” statement rather than relying only on the primary botanical list.
The label also states that the product is manufactured in the United States with globally sourced ingredients. This describes the manufacturing and sourcing statement printed on the package and should not be interpreted as an independent certification of the ingredients or finished product.
Erexafil Is a Dietary Supplement and Is Not FDA Approved
Erexafil is labeled as a dietary supplement. It is not presented in this guide as an FDA-approved drug, and consumers should not interpret the existence of Supplement Facts, a U.S. distributor address or a U.S. manufacturing statement as evidence of FDA approval of the finished product.
NCCIH explains that, unlike drugs, dietary supplements are not approved by the FDA before they are marketed to the public. Manufacturers and distributors are responsible for evaluating safety and labeling and for meeting applicable regulatory requirements.
That regulatory distinction is important because the phrase “FDA approved” is sometimes used incorrectly in discussions of supplements. This release makes no such representation about Erexafil.
What the 2026 Erexafil Guide Does Not Claim
The consumer guide does not claim that Erexafil has been demonstrated in a controlled clinical trial to produce a specific health outcome. No research source referenced in this release evaluated the complete Erexafil formulation shown on the current bottle.
The guide also does not assume that a research finding involving turmeric, beetroot, nettle, ashwagandha or Tongkat Ali will apply to Erexafil. Ingredient amounts, extract types and research conditions differ, and several studies use preparations that cannot be directly compared with the product label.
Similarly, the 10:1, 20:1 and 4:1 extract ratios printed on the bottle describe formulation characteristics. Those ratios are not presented here as evidence that one extract is stronger, safer or more effective than another.
Erexafil Product Information at a Glance
The current bottle identifies Erexafil as a 30-capsule dietary supplement with one capsule per serving and 30 servings per container. Its Supplement Facts panel lists turmeric root powder at 150 mg, beet root powder at 150 mg, nettle root extract at 50 mg, ashwagandha root extract at 50 mg and Tongkat Ali root extract at 50 mg.
Official Website: geterexafil.com
Suggested use is one capsule daily with water. The label includes specific storage and caution instructions and identifies additional capsule-manufacturing ingredients separately from the five botanicals.
Consumers researching Erexafil ingredients, Erexafil Supplement Facts, Erexafil dosage, Erexafil safety or Erexafil reviews should compare information online with the current physical label. If there is a material difference between an older webpage and the bottle received, the current package should be reviewed before use and questions can be directed to the distributor.
Research References
The National Center for Complementary and Integrative Health provides consumer research summaries covering turmeric and ashwagandha. Its turmeric review notes that available formulations vary considerably and that current evidence does not support definitive conclusions for many promoted uses.
NCCIH’s ashwagandha review similarly notes variation across clinical preparations and study designs while identifying possible adverse effects and medication interactions that may be relevant to individual consumers.
The European Medicines Agency maintains an herbal monograph and assessment documentation for nettle root, Urtica dioica and Urtica urens. That documentation relates to nettle as a botanical medicine and does not evaluate the Erexafil formulation.
Published systematic reviews indexed by the National Library of Medicine’s PubMed database have also evaluated nitrate-rich beetroot preparations. Those studies generally use defined nitrate quantities or beetroot-juice interventions, which cannot be directly matched to the 150 mg of beet root powder shown on the Erexafil label because its nitrate content is not disclosed.
None of these sources mentions, tests or endorses Erexafil. They are included only to provide context about the individual botanical ingredients and to explain why ingredient-level research should not be interpreted as evidence for the finished product.
About Erexafil
Erexafil is a 30-capsule dietary supplement distributed from Ogden, Utah. The current Supplement Facts panel lists individually quantified amounts of turmeric root powder, beet root powder, nettle root extract, ashwagandha root extract and Tongkat Ali root extract.
The 2026 consumer-information guide is intended to provide a consolidated reference for the product’s current ingredient panel, serving instructions and safety information. Erexafil is marketed as a dietary supplement and is not represented in this release as an FDA-approved drug or as a product intended to diagnose, treat, cure or prevent disease.
Media and Order Information
Kevin Moore
Media Relations Manager
Erexafil
Customer Support: support@geterexafil.com
Order Status Inquiries: +1 (323) 391-7443
Mailing Address: PO Box 12730, Ogden, UT 84412
Consumer Information Disclaimer
This release provides general information concerning the ingredients, serving instructions and safety statements appearing on the current Erexafil product label. It does not constitute medical advice, independent laboratory testing, clinical evidence for the finished formulation or a guarantee of any particular result.
Consumers should review the complete product label before use and consult an appropriate healthcare professional when they use medication, have an existing medical condition or have questions about botanical supplements. Research cited in this release concerns individual ingredients or general supplement information and should not be interpreted as research conducted on or endorsement of Erexafil.
